{"id":"W4391303156","doi":"10.1200/jco.2024.42.4_suppl.382","title":"Real-world treatment outcomes in patients with advanced renal cell carcinoma who receive axitinib plus pembrolizumab in the first-line setting in Canadian cancer centers.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Sunnybrook Health Science Centre; McMaster University; Université Laval; Centre Hospitalier de l’Université de Montréal; Health Sciences Centre; CancerCare Manitoba; University Health Network; Dalhousie University; University of Alberta; University of Calgary; Princess Margaret Cancer Centre; Juravinski Cancer Centre; University of Manitoba; Centre hospitalier universitaire de Québec; University of Ottawa; McGill University; McGill University Health Centre","funders":"","keywords":"Medicine; Axitinib; Pembrolizumab; Renal cell carcinoma; Oncology; Internal medicine; Cancer; Kidney cancer; Renal carcinoma; Cancer treatment; Immunotherapy; Sunitinib","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006514787,0.0002725696,0.000428606,0.0005296206,0.001173379,0.001040223,0.0005881885,0.0004870944,0.001166562],"category_scores_gemma":[0.002120708,0.0001747825,0.0005702986,0.001690848,0.0003671973,0.0004248405,0.0005449719,0.0007309055,0.0001599231],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0157461,"about_ca_system_score_gemma":0.009484073,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.6709496,"about_ca_topic_score_gemma":0.7789286,"domain_scores_codex":[0.9992544,0.00006326316,0.00004709657,0.0001169825,0.0002633468,0.0002549168],"domain_scores_gemma":[0.9983183,0.0001135391,0.000703409,0.0000417855,0.0003059215,0.0005169404],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0005931831,0.0001124737,0.9908749,0.00006642681,0.0001264996,0.0001496945,0.0002046814,0.0003278716,0.0001186666,0.00004085924,0.001737249,0.005647624],"study_design_scores_gemma":[0.0000712154,0.0002578446,0.9975183,0.00002914477,0.00006502548,0.000175121,0.0002790938,0.0004045031,0.00005914621,0.00002927997,0.001094776,0.0000165891],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.99299,0.0009486419,0.00004495391,0.000367417,0.0000100582,0.00005559013,0.004367452,0.000006948021,0.001208898],"genre_scores_gemma":[0.9958555,0.0002810333,0.00007819809,0.000147076,0.00001294335,0.00001937348,0.003433211,0.000002013326,0.0001707531],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3290504,"threshold_uncertainty_score":0.6619764,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05276805426933315,"score_gpt":0.3942933945068575,"score_spread":0.3415253402375243,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}